HUG incorporates RTsafe’s products and services for stereotactic radiosurgery quality assurance into clinical practice.

RTsafe today announced that its Personalized PseudoPatient™ product has received a 2019 R&D 100 Award from R&D World Magazine as one of the 100 most technologically significant products of the past year.

Single isocenter multi-focal stereotactic radiosurgery is a challenging treatment approach for multiple brain metastases. This study aims to experimentally quantify the overall spatial uncertainties of such treatment techniques.

RTsafe announces that Elekta is using RTsafe’s PseudoPatient™ technology for End-to-End stereotactic quality assurance (QA) in the new Elekta Assurance solution to deliver safe and efficient brain radiotherapy.

​​​​​​​A research collaboration between RTsafe and Elekta resulted to the world’s first experimental quasi-real-time demonstration of dose accumulation during a clinical IMRT irradiation, a true breakthrough in radiotherapy.

RTsafe announces that it has signed JW Pacific as its exclusive distributor for Hong Kong, Macau, Taiwan & South Korea.

Meet RTsafe in Chicago, Illinois, Sept. 15-18, at booth # 4837.

The new office is located within the Cambridge Innovation Center.

The Seal of Excellence is a quality label awarded to project proposals submitted to Horizon 2020, the EU's research and innovation funding program.

Read the latest article on RTsafe's Personalized PseudoPatient™ published at Digital Trends.